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Angioplasty and bypass grafting are common
procedures for the treatment of significant athero-
sclerotic arterial occlusive disease, and intimal hyper-
plasia is a common cause for reconstructive failure.
Intimal hyperplasia is a complex process in which the
blood vessel intima becomes thickened because of
the proliferation and migration of medial vascular
smooth muscle cells (VSMCs) and subsequent extra-
cellular matrix deposition. Relatively little attention
has been given to the role of the extracellular matrix
in intimal hyperplasia formation. 
Thrombospondin-1 (TSP-1) is a transient extra-
cellular matrix glycoprotein that is virtually absent in
the normal vessel, but accumulates in acutely injured
vessels, some areas of intimal hyperplasia, and ather-
osclerotic plaques.1-3 Recent evidence suggests that
TSP-1 can stimulate VSMC migration4 and prolifer-
ation.5 However, little is known about VSMC acti-
vation of signaling pathways for TSP-1-induced
migration. 
Focal adhesion kinase (FAK) is a cytoplasmic or
nonreceptor protein-tyrosine kinase localized in focal
adhesions. These intracellular densities are located in
the abluminal side of the cell and have been implicat-
ed in the regulation of cell morphology and migra-
tion in response to cell adhesion to extracellular
matrix proteins.6 Subcellular localization and regula-
tion of FAK by engagement of cell-surface integrins
and modulators of cytoskeletal organization suggest
that FAK is important in the regulation of cell adhe-
sion, morphology, and motility. 
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Purpose: Vascular smooth muscle cell (VSMC) proliferation and migration are important
events in the development of intimal hyperplasia. Thrombospondin-1 (TSP-1), an extra-
cellular matrix protein present in intimal hyperplastic lesions, has been shown to stimu-
late VSMC proliferation and migration. We hypothesized that the focal adhesion plaque,
specifically the focal adhesion kinase (FAK) protein, may be important in the signal
transduction pathway for TSP-1-induced VSMC migration.
Methods: Growth-arrested bovine aortic VSMCs were treated with TSP-1 (20 m g/mL)
for set intervals (15, 30, and 120 minutes) and compared with VSMCs grown in serum-
free medium (negative control) or in the presence of a known mitogen and chemotactic
factor, platelet-derived growth factor (10 ng/mL; positive control). Crude cell lysates
and anti-FAK immunoprecipitates were assayed for phosphotyrosine activity by means
of antiphosphotyrosine immunoblotting. The blots were quantified by means of densi-
tometric analysis.
Results: TSP-1 increased tyrosine phosphorylation of three protein bands of molecu-
lar weights 68, 125 (consistent with FAK), and 180 kDa. Immunoprecipitation with
FAK antibody, followed by antiphosphotyrosine immunoblotting, indicated that there
was an increase in tyrosine phosphorylation of FAK at 15, 30, and 120 minutes in the
TSP-1-treated groups (P < .05).
Conclusion: Tyrosine phosphorylation of FAK is induced by TSP-1 stimulated VSMCs.
This suggests an outside-inside signaling pathway by which TSP-1 stimulates VSMC
migration. (J Vasc Surg 1999;29:1031-6.)
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We hypothesized that migration of VSMCs in the
presence of TSP-1 is dependent on FAK. The activa-
tion of FAK in TSP-1 stimulated VSMCs was studied. 
METHODS
Vascular smooth muscle cell culture. Bovine
aortic VSMCs were isolated, as previously described,
and used in early passage.7 VSMCs were seeded in
Dulbecco’s modified Eagle’s medium (Gibco BRL,
Gaithersburg, Md) containing 10% fetal bovine
serum in primary culture at high density (2 · 104
cells/cm2). VSMC subconfluent monolayers were
growth-arrested (48 hours) in serum-free medium
before all experiments. VSMCs were identified by
their typical morphologic appearance and confirmed
with a -VSMC actin staining.
Thrombospondin-1. Purified TSP-1, derived
from human platelets, was purchased from Gibco
BRL (Gaithersburg, Md) and was also provided by
Jack Lawler, PhD (Beth Israel Deaconess Medical
Center, Boston, Mass). VSMCs were exposed to
TSP-1 (20 m g/mL) for as long as 120 minutes.
Preliminary studies showed that this concentration of
TSP-1 induces a robust migration of VSMCs.8 In
additional experiments, VSMCs were exposed to 10
ng/mL of platelet-derived growth factor BB (PDGF,
BB homodimer, human recombinant; Calbiochem,
La Jolla, Calif) for 30 minutes as a positive control.
Immunoprecipitation. VSMCs were lysed with
radio immuno protection assay buffer after experimen-
tation and analyzed as previously described.9 Protein
G-sepharose (Pharmacia LKB, Biotechnology, Upsala,
Sweden) and anti-FAK antibodies (mouse monoclon-
al, Transduction Laboratories, Lexington, Ky) were
incubated for 2 hours at room temperature. Aliquots
containing the same amount of protein were then
immunoprecipitated with protein G-sepharose and
antibody complex overnight at 4°C. The immune
complexes were washed and released from protein G-
sepharose and separated by sodium dodecyl sul-
fate/7.5% polyacrylamide.
Western blot analysis. After electrophoresis,
crude cell lysates or the immunoprecipitated protein
for total FAK were transferred to 0.45 m m nitrocel-
lulose, and the blots were incubated in 5% nonfat
dry milk for 1 hour at room temperature and then
incubated with an antiphosphotyrosine mouse mon-
oclonal antibody (RC20H; New England Biolabs,
Beverly, Mass) or anti-FAK antibodies for 2 hours at
room temperature.9 Blots were washed four times
with washing buffer (137 mmol/L NaCl, 0.1%
Tween-20, 20 mmol/L TrisHCl, pH 7.5) and incu-
bated with horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (New England
Biolabs, Beverly, Mass).
Immunoreactivity was determined by means of
enhanced chemiluminescence (Amersham, Arlington
Heights, Ill) and quantified with a Visage 2000 den-
sitometer (BioImage, Ann Arbor, Mich).
Statistical analysis. Densiometry was per-
formed for activated FAK, and normalized data was
recorded as the mean ± the standard error of the
mean and analyzed by one-way analysis of variance.
A P value less than .05 was considered significant.
RESULTS 
Crude lysates from VSMCs exposed to TSP-1
were assayed for phosphotyrosine activation by
means of antiphosphotyrosine immunoblotting. As
demonstrated in Fig 1, TSP-1 increased tyrosine
phosphorylation of at least three proteins of molec-
ular weights 68 kDa, 125 kDa, and 180 kDa. 
We hypothesized that the 125 kDa band repre-
sented activated FAK (molecular weight, 125 kDa).
VSMC lysates were immunoprecipitated with FAK
antibody, and the precipitates were tested for phos-
phorylated tyrosine residues by means of immunoblot-
ting with an antiphosphotyrosine antibody RC20H. A
representative blot is shown in Fig 2A. Tyrosine phos-
phorylation of FAK was detected within 15 minutes
and sustained for as long as 2 hours. Anti-FAK
immunoblotting was performed (Fig 2B) to confirm
equal loading of protein and unaltered FAK levels. The
results in Fig 2 confirmed that the 125 kDa band
shown in Fig 1 contained phosphorylated FAK. 
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Fig 1. Growth-arrested confluent vascular smooth mus-
cle cells were treated with thrombospondin-1 (20
m g/mL) for 0, 15, 30, and 120 minutes. Cell lysates were
subjected to antiphosphotyrosine (RC20H) immunoblot-
ting. Three prominent bands were identified at 68 kDa,
125 kDa, and 180 kDa.
Densitometry of the phosphorylated FAK from
four different experiments was performed and ana-
lyzed. As shown in Fig 3, there was a significant
increase in tyrosine phosphorylation of FAK at 15
(2.39 ± 0.83 fold), 30 (2.31 ± 0.84 fold), and 120
(2.64 ± 0.95 fold) minutes in the TSP-1-treated
groups, in comparison with VSMCs exposed to
serum-free medium alone (P < .05). There was no
difference in the amount of FAK phosphorylation
between TSP-1 at all time points and when com-
pared with VSMC stimulation with PDGF (2.54 ±
1.05 fold) for 30 minutes.
DISCUSSION
In this study, we have demonstrated the novel
finding that culture of VSMCs on TSP-1 induced
tyrosine phosphorylation of several proteins, includ-
ing FAK. Activation of FAK, as measured by means
of tyrosine phosphorylation of FAK, has been
reported to be part of a signaling cascade, which is
critical in VSMC migration.6 Our observation that
TSP-1 induces FAK phosphorylation of VSMCs
supports our hypothesis that TSP-1-induced VSMC
chemotaxis is dependent on FAK activation. Our
data demonstrate that FAK activation by TSP-1 was
significant within 15 minutes, was sustained for 2
hours, and is consistent with other studies in differ-
ent cell types and experimental models.9 It should
be emphasized, however, that 15 minutes of expo-
sure to TSP-1 simply represents the time by which
significant levels of tyrosine phosphorylated FAK
could be visualized and does not exclude the possi-
bility that FAK phosphorylation occurs earlier.
The identity of the phosphorylated bands shown
in Fig 1 are not known. Paxillin is a 68 kDa protein
that is a putative substrate for FAK. It is interesting to
speculate that the band at 68 kDa shown in Fig 1 is
consistent with tyrosine phosphorylated paxillin that
has been shown in other experimental models.9
Additional investigation is needed to directly confirm
activation of paxillin. Furthermore, it is possible that
there are other proteins with molecular weights of
approximately 125 kDa that may be tyrosine phos-
phorylated in VSMCs grown on TSP-1. One possible
candidate is vinculin, which is a 117 kDa cytoskeletal
protein that is associated with focal adhesion plaques
and also contains tyrosine residues that can be phos-
phorylated.10 It is less clear what the potential candi-
date for the 180 kDa protein could be, although one
prospect is the PDGF tyrosine kinase receptor.11
Activation of FAK has been demonstrated to
interact with the actin cytoskeletal organization asso-
ciated with cell migration.6 As mentioned earlier, FAK
phosphorylation can lead to paxillin phosphorylation
with subsequent activation of actin-binding proteins,
leading to actin reorganization.10 In addition, FAK
may interact with other cytoplasmic signaling path-
ways, such as protein kinase C or mitogen-activated
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Fig 3. Phosphorylation of focal adhesion kinase quanti-
fied by means of densitometry in four different experi-
ments. Normalized data demonstrates enhanced tyrosine
phosphorylation of focal adhesion kinase for throm-
bospondin-1 stimulated vascular smooth muscle cells,
compared with cells in serum-free medium (P < .05), and
was no different from cells exposed to 10 ng/mL platelet-
derived growth factor (positive control).
Fig 2. Growth-arrested vascular smooth muscle cells
were treated with thrombospondin-1 (20 m g/mL) for 15,
30, and 120 minutes. Serum-free medium was the nega-
tive control. Cell lysates were subjected to immunoprecip-
itation with anti-focal adhesion kinase antibodies. A,
Antiphosphotyrosine immunoblotting demonstrates tyro-
sine phosphorylation of focal adhesion kinase, hence acti-
vation. B, Immunoblotting with anti-focal adhesion
kinase antibodies confirms equal loading of protein and no
change in focal adhesion kinase levels. 
protein kinase, both of which have been associated
with VSMC migration.12-14 Preliminary studies by
our laboratory suggest that these pathways may be
activated in VSMCs exposed to TSP-1 (unpublished
observation). It may also be possible that the activa-
tion of these classic signaling pathways by TSP-1
occurs downstream of FAK activation.
The interaction of the extracellular matrix with
the focal adhesion plaque and their role in VSMC
migration and the development of intimal hyperpla-
sia still remain to be better defined. Most research
regarding the extracellular matrix protein TSP-1 has
examined TSP-1’s role in platelet function, tumor
biology inflammation, and wound healing. Evidence
concerning the functional importance of TSP-1 in
modulating VSMC phenotype is relatively sparse.
What is known through tissue culture studies is that
VSMCs contain, secrete, and can incorporate TSP-1
into the extracellular matrix.5 In addition, TSP-1 is
an important cell-adhesive protein for VSMCs.15
TSP-1 induces VSMC migration with a TSP-1
concentration-dependent manner.4,8,16 By using
antibodies specific to different domains on TSP-1, it
has been previously demonstrated that the C-termi-
nal domain mediates TSP-1-induced VSMC chemo-
taxis in bovine pulmonary artery cells.4 In addition,
an a V-containing integrin receptor also appeared to
be involved in TSP-1-induced VSMC migration.
Integrins are known adhesive receptors for the extra-
cellular matrix, are capable of transmitting intracel-
lular signals, and are associated with cell adhesion
and migration.17-19
TSP-1-induced protein tyrosine phosphorylation
may be involved in the regulation of the structure
and function of focal adhesions and the signaling
pathways. It has been shown that nonspecific tyrosine
kinase inhibitors (genistein, herbimycin, and tyr-
phostin A23) abolished TSP-1-induced VSMC
migration and proliferation.8,16 The results of these
inhibitor studies suggest TSP-1-induced VSMC
migration and proliferation activates tyrosine kinase
signaling proteins and is consistent with our findings
that TSP-1 induces tyrosine phosphorylation of FAK. 
Consistent with the concept of TSP-1 inducing
protein-tyrosine phosphorylation are findings that
have been shown for other cell types. For example,
in melanoma cells, integrin associated protein (the
carboxyl-terminal domain receptor of TSP-1 that is
associated with migration) exerts at least part of its
effect on signal transduction through protein-tyro-
sine kinase.20 More specifically, there was increased
tyrosine phosphorylation of FAK and paxillin in
melanoma cells exposed to TSP-1. In addition,
enhanced spreading of melanoma cells by TSP-1 was
inhibited by the tyrosine kinase inhibitors genistein
and herbimycin. In platelets, the integrin associated
protein has also been found to form a complex with
the platelet integrin a IIb b 3 that will associate with
FAK and result in the localization to the platelet sur-
face and fibrin clot.21 Additionally, phosphatidyl-
inositol 3¢ -kinase (PI 3-kinase) is activated in TSP-
1-stimulated melanoma and aortic endothelial
cells.20,22 PI 3-kinase, a family of lipid kinases asso-
ciated with the tyrosine kinases, is a component of
the cell-signaling pathway mediating TSP-1-induced
disassembly of focal adhesions and reorganization of
the actin cytoskeleton in aortic endothelial cells.22
In conclusion, TSP-1 induced tyrosine phosphory-
lation of proteins in VSMCs and, more specifically,
tyrosine phosphorylation of FAK. This is the first
demonstration of outside-inside signaling with TSP-1
for VSMCs; ie, extracellular TSP-1 can directly activate
intracellular FAK, which may lead to cell migration.
The consequences of FAK activation on cell migration
and the interaction with integrins and extracellular
matrix proteins such as TSP-1 still need to be eluci-
dated. Further investigation is also warranted to deter-
mine whether the focal adhesion protein, FAK, is crit-
ical in TSP-1-induced VSMC migration. 
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Dr Michael Watkins (Boston, Mass). Dr Gahtan, this
was very well done. I have a couple of questions. First, have
you done any inhibitor studies for this phosphorylation?
Specifically, have you used genistein or tyrphostin to deter-
mine if the phosphorylation can be inhibited? Second, is
there a dose-response curve with respect to the phospho-
rylation of focal adhesion kinase? And last, is the phos-
phorylation of focal adhesion kinase related to the arginine-
glycine-aspartic acid domain of thrombospondin-1? Thank
you for an excellent presentation.
Dr Vivian Gahtan. In response to your first question
regarding the inhibitor studies, we have performed
inhibitor studies, and the data will be presented at the
Surgical Forum this October. In brief, the tyrosine kinase
inhibitors genistein and herbimycin A inhibited chemo-
taxis. That would support that focal adhesion kinase phos-
phorylation would be involved in thrombospondin-1-
induced smooth muscle cell migration.
In response to your second question, we have not per-
formed a dose-response curve specifically for focal adhe-
sion kinase activation, and I think that needs to be done.
We used 20 m g/mL for all experiments, because that hap-
pened to be a concentration that was consistent to stimu-
late both migration and proliferation. We stayed with that
concentration, but I suspect we could use even lower con-
centrations and obtain similar results.
The third question was regarding the RDG domain
and thrombospondin-1. The C-termal domain is the one
that has been associated with vascular smooth muscle cell
migration. There are only a few studies that address migra-
tion and domain. There is a peptide to inhibit the RGD
domain, and two studies had conflicting results. The first
was by Yabkowitz, in which he used bovine pulmonary
artery smooth muscle cells. When inhibiting the RGD
domain, chemotaxis was not affected. However, when
Patel used saphenous vein smooth muscle cells, he did
inhibit chemotaxis, by using the same peptide inhibitor.
So, I think the role of the RGD domain for throm-
bospondin-1-induced smooth muscle cell chemotaxis is
not completely clear.
Dr John Mannick (Boston Mass). I, too, enjoyed the
paper very much.
I am concerned about only one thing, and that is the
microgram amounts of thrombospondin you were using
in all your assays. It seems to be a very high concentration
for something that has a physiological effect. Is that truly
relevant to the concentration of thrombospondin in an
injured artery, for example?
Your control positive platelet-derived growth factor
concentration was down in a more reasonable nanogram
amount to achieve the same effect.
With these microgram amounts, is this a pharmaco-
logic phenomenon you’re describing, or does this really
represent physiology?
Dr Gahtan. We know a little bit about the concentra-
tion of thrombospondin-1 in human tissues. Normal plas-
ma levels of thrombospondin are in nanograms per milli-
liter, with a range of 40 to 250 ng/mL.
In tissue, for example, there are very few tissues in
which they’ve actually measured a concentration, and in
DISCUSSION
breast cyst fluid, you can see concentrations as high as 55
m g/mL. But most tissues, I suspect, have lower concen-
trations. Nobody has ever quantified the amount or con-
centration of thrombospondin in atherosclerotic plaque or
in an intimal hyperplastic lesion; there have been relative
amounts measured, but not an actual concentration.
Thrombospondin is an extracellular matrix protein,
and when we look at other in vitro studies with extracel-
lular matrix proteins, such as fibronectin, the concentra-
tions used are in micrograms per milliliter and not in
nanograms per milliliter, as are most of the growth factors.
So, I am not completely sure of the answer to your
question, but, relative to other extracellular matrix pro-
teins, we are using similar concentrations.
Dr K. Craig Kent (New York, NY). Vivian, this is
great work, and I think it goes with the recent theme,
which is that matrix proteins are far more important than
previously thought, for the proliferation and migration
that’s associated with intimal hyperplasia.
I have a couple of thoughts.
The first is just to reenforce Mike’s thoughts that you
should perform concentration-response curves. In our
own work with focal adhesion kinase, if you stimulate with
platelet-derived growth factor, at low concentrations you
get a profound response, and at higher concentrations, the
response decreases. I think that understanding this with
your particular model is going to be useful.
Second, I think in the past few years there’s been a great
suspicion that focal adhesion kinase is associated with migra-
tion, and the reason for that is the ability to stimulate migra-
tion and show a rise in tyrosine phosphorylation of focal
adhesion kinase. There was a recent article with a knockout
mouse model, suggesting that if focal adhesion kinase was
absent, you still were able to have good attachment and
good migration. So, now I think there’s some suspicion that
focal adhesion kinase may, in fact, not be so important for
migration, proliferation, attachment, or in the other types of
physiologic events, as previously thought.
What are your thoughts about this and how do you
plan to sort that out?
Dr Gahtan. I think that focal adhesion kinase is an
upstream signaling pathway, that is associated with migra-
tion, but it’s not the only pathway associated with migra-
tion. So, I think that it’s at least contributing. We don’t
have conclusive evidence that activation of focal adhesion
kinase is what causes thrombospondin-1-induced smooth
muscle cell migration; however, I think with the transfec-
tion studies, we will be able to resolve that issue with con-
clusive, functional evidence. For example, we’ve shown
activation of the mitogen-activated protein kinases, with
activation of extracellular signal regulated protein kinase 1
and 2 in our preliminary data, and there’s a lot of data to
support that the activation of MAP kinase is associated
with migration. So, there are other pathways and other
mechanisms for which it could happen. Whether focal
adhesion kinase is activating MAP kinase, or whether there
is direct activation of MAP kinase from thrombospondin-
1, is something that still needs to be delineated.
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